$CLBT

Barter David sold $683K of CLBT

Barter David (Chief Financial Officer) sold 41,734 shares of Cellebrite DI Ltd. (CLBT) at $16.38 ($0.68M total) on 2026-07-08.

Original reporting
SEC EDGAR · Barter David
Published Jul 9, 2026, 8:10 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 9, 2026, 8:16 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$CLBT
Neutral
medium confidence
Mentioned
$CLBT
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CLBTNeutralLow
01

Why it matters

The newest fact is the specific sale details (shares, price, total value, and holdings after sale) plus the note that there was no pre-arranged 10b5-1 plan.

02

Market read

Traders may monitor CLBT for follow-on insider activity, but this single Form 4 sale alone is unlikely to drive a durable repricing.

03

What to watch

The article does not state the insider’s total compensation, tax obligations, or whether other sales occurred, so interpreting directionality for fundamentals is risky.

Relevance 5/10Novelty 3/10Timing: after-hours/next-session context from a newly filed Form 4 (filed 2026-07-09)

Background

The article is an SEC Form 4 insider transaction disclosure for Cellebrite DI Ltd., reporting an open-market sale by the CFO.

Company-level read

Ticker impact

$CLBTNeutralMedium confidence
Context

Cellebrite CFO Barter David sold 41,734 shares on 2026-07-08 at $16.3756, totaling $683,419.29, per Form 4.

Expected impact

Likely limited near-term price impact; any effect is sentiment-driven and typically fades unless accompanied by other disclosures.

Evidence & confidence

The filing provides transaction size, price, and post-sale holdings, but does not include new company performance, guidance, or legal/regulatory developments.

Market effects

No clear sector read-across; insider sales are company-specific and often non-informational.

None.

None.

Counterpoint

Insider sales can be planned for liquidity or diversification and may not reflect negative fundamentals, especially when the filing is a standard open-market transaction.

Key entities

  • Cellebrite DI Ltd.

    US-listed company (CLBT) whose CFO filed an insider sale on Form 4.

  • Barter David

    Chief Financial Officer who sold 41,734 shares on 2026-07-08.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CLBTMedAI 8/10

Cellebrite (CLBT) Q2 2026 Earnings Call Transcript

Cellebrite (CLBT) announced Shiv Ramji as its new CEO, replacing Tom Hogan. The company missed Q2 revenue expectations due to delayed large transactions and lower-than-expected ARR uplift. Despite this, they raised their full-year adjusted EBITDA target. Ramji outlined plans to improve sales execution and forecasting discipline. The company sees growth in new products and federal business, with a 25% increase in Defense and Intelligence ARR.

$CLBTMedAI 8/10

Why Cellebrite DI (CLBT) Is Down 30.4% After Cutting 2026 Outlook And Announcing CEO Transition

Cellebrite DI Ltd. reported half-year 2026 results and cut its full-year revenue outlook to US$555 million to US$561 million, implying 17% to 18% growth. The company also announced a CEO transition, with Shiven Ramji succeeding Thomas E. Hogan. The guidance reduction, weaker profitability, and delayed large government contracts contributed to a sharp stock drop.

$CLBTMedAI 8/10

Cellebrite DI Ltd. Q2 2026 Earnings Call Summary

Cellebrite DI Ltd. reported Q2 2026 results below expectations, citing delayed large transactions and procurement hurdles tied to foreign entity status. Full-year ARR guidance was cut to $550m–$560m, while adjusted EBITDA was raised to $153m–$159m. Management said Insights installed base reached 65% and Genesis launched with $400k ARR.